05:13 PM EDT, 10/15/2025 (MT Newswires) -- Viatris ( VTRS ) said late Wednesday it closed the acquisition of Aculys Pharma, including rights to develop and commercialize central nervous system therapy assets pitolisant and spydia, in Japan and some markets in the Asia-Pacific region.

Under the agreement, Viatris ( VTRS ) made an upfront payment to Aculys Pharma, with provision for additional payments based on achieving certain regulatory and commercial milestones, according to a statement.

This acquisition expands Viatris' ( VTRS ) portfolio of products in Japan, many of which are undergoing phase 3 trials, the company said.